The tesamorelin cognition trial

The study population

The controlled trial enrolled 152 older adults, including 66 with mild cognitive impairment. It was randomized, double-blind and placebo-controlled, and the intervention lasted 20 weeks. The GHRH analogue was tesamorelin.

That last name matters here. The paper’s title says “growth hormone-releasing hormone,” which can sound broader than the actual intervention. Credit ought to stay with the compound and population that produced the finding. This is human cognition evidence for a particular GHRH analogue, rather than an invitation to substitute another one.

The cognitive and metabolic outcomes

The trial reported a favorable effect on cognition, including executive function, alongside a 117% increase in IGF-1 within the physiologic range and a 7.4% reduction in percent body fat. Adverse events were described as mild.

For me, cognition leads the discussion. The large IGF-1 change is easy to make into a headline, yet the ability being investigated gives the experiment its purpose. These outcomes were reported together; they still require separate judgments about their value.

The body-fat figure describes a reduction in percent body fat. It does not report a 7.4% loss of total body weight. Preserving that distinction prevents an unrelated weight-loss claim from slipping into a discussion of cognition.

Everyday cognitive activities

I picture a useful cognitive result carrying into an argument, a decision, an engrossing conversation. Those are my hopes for an anti-aging intervention, extending beyond the outcomes reported in this paper. The reported finding concerns cognition over the trial’s 20 weeks.

The next account capable of persuading me would connect measured improvement with activities people value and show how long it lasts. Its metabolic consequences would need to sit close enough to the cognitive findings for a fair judgment of the trade. A favorable test result can justify that interest without settling the whole question.

The congenital-deficiency comparison

A brain-imaging comparison in adults with congenital untreated GH deficiency complicates any claim that an active GH axis is essential to avoiding accelerated brain aging. It studied a very different population and asked a structural question.

Forcing a verdict for or against all GHRH research would ask these studies to settle a question neither tested. Their disagreement is useful precisely because they put different propositions on the table. The brain-age page follows that narrower dissent; the metabolic account considers findings elsewhere in the body.